SEOUL: Samsung Biologics Co Ltd, the biopharmaceutical contract manufacturing affiliate of Samsung Group, said on Thursday that it decided to pursue an initial public offering in South Korea in 2016.
The company said in a statement that it will pick advisors for the IPO in May.
Analysts have estimated the company's market capitalization to be around 10 trillion won ($8.72 billion) or more.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
